Accessibility Menu
Arcellx logo

Arcellx(NASDAQ) ACLX

This security has been delisted. This page is retained for historical reference.

Arcellx last closing stock price
MetricPriceDate
Last closeUSD 115.072026-04-27
Arcellx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.06%USD 115.002026-04-20
1 month+0.44%USD 114.572026-03-27
3 month+67.96%USD 68.512026-01-27
Year to date+76.49%USD 65.202025-12-31
1 year+80.62%USD 63.712025-04-25
3 year+169.61%USD 42.682023-04-28
Since inception+584.94%USD 16.802022-02-04

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

ACLX Financials

Key Financial Metrics (TTM)

Gross Margin

-64.81%

Operating Margin

-1135.61%

Net Income Margin

-1027.25%

Return on Equity

-55.42%

Return on Capital

-50.76%

Return on Assets

-37.90%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$14.44M

Operating Income

-$253.08M

EBITDA

-$197.97M

Operating Cash Flow

-$210.26M

Capital Expenditure

-$2.33M

Free Cash Flow

-$212.59M

Cash & ST Invst.

$450.33M

Total Debt

$96.26M

Arcellx Performance Analysis

Arcellx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 110,319,000N/A
20242024-12-31USD 107,936,000-2.2%
20252025-12-31USD 22,286,000-79.4%
Arcellx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-46.8%
Q22025-06-30-7.1%
Q32025-09-30-34.5%
Q42025-12-31-66.6%
Arcellx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.28135.3%
20232023-12-31USD -1.47-65.6%
20242024-12-31USD -2.0036.3%
20252025-12-31USD -4.07102.9%
Arcellx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-28.4%
Q22025-06-3016.8%
Q32025-09-30-5.3%
Q42025-12-31-1.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.65M

-89.2%

Gross Profit

$13.00K

-99.9%

Gross Margin

0.79%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

163

N/A

Net Income

-$58.11M

-23.4%

EBITDA

-$32.23M

+26.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$450.33M

-23.3%

Total Debt

$96.26M

+78.0%

Accounts Receivable

$3.60M

N/A

Inventory

$0.00

N/A

Long Term Debt

$88.68M

+90.5%

Short Term Debt

$7.58M

+0.6%

Return on Assets

-37.90%

N/A

Return on Invested Capital

-50.64%

N/A

Free Cash Flow

-$58.94M

-24.0%

Operating Cash Flow

-$58.18M

-26.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALKSAlkermes plc
$52.85+2.18%
NAMSNewAmsterdam Pharma Company N.V.
$32.34+9.00%
AKROAkero Therapeutics, Inc.
$54.65+0.00%
PTGXProtagonist Therapeutics, Inc.
$138.31+3.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
PATHUiPath
$12.04-0.01%
NUNu Holdings
$14.39+0.03%
TAT&T
$22.26+0.01%
MARAMara Holdings
$12.25+0.05%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.